CAMBRIDGE, Mass., Sept. 3, 2019 /PRNewswire/
-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI),
a clinical-stage biotechnology company developing IPI-549, a
potentially first-in-class immuno-oncology product candidate that
selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma),
today announced that management will be participating in the
following two upcoming conferences this month:
Wells Fargo 2019 Healthcare
Conference: Adelene Perkins, Infinity's Chief Executive
Officer, will present at Wells Fargo Securities14th
Annual Healthcare Conference on Wednesday,
September 4, 2019, at 1:50 p.m.
ET at the Westin Copley Place in Boston, MA. A live webcast of the presentation
will be available on the Investors/Media section of Infinity's
website at www.infi.com and will be available for 30 days following
the event.
Morgan Stanley 17th Annual Global Healthcare
Conference: Infinity's management team will participate in the
Morgan Stanley 17th Annual Global Healthcare Conference
on Wednesday, September 11, 2019, at
the Grand Hyatt New York, New
York.
About Infinity
Infinity is an innovative
biopharmaceutical company dedicated to advancing novel medicines
for people with cancer. Infinity is advancing IPI-549, a
first-in-class, oral immuno-oncology development candidate that
selectively inhibits PI3K-gamma, in multiple clinical studies.
MARIO-1 is an ongoing Phase 1/1b
study evaluating IPI-549 as a monotherapy and in combination with
Opdivo® (nivolumab) in approximately 225 patients with
advanced solid tumors including patients refractory to anti-PD-1
therapy. MARIO-275 and MARIO-3 have recently initiated. MARIO-275
is a global, randomized, combination study of IPI-549 combined with
Opdivo in I/O naïve urothelial cancer patients. MARIO-3 is the
first IPI-549 combination study in front-line advanced cancer
patients and is evaluating IPI-549 in combination with
Tecentriq® and Abraxane® in front-line TNBC
and in combination with Tecentriq and Avastin® in
front-line RCC. With the addition of MARIO-275 and MARIO-3 to the
ongoing MARIO-1 study, Infinity will be evaluating IPI-549 in the
anti-PD-1 refractory, I/O-naïve and front-line settings. For more
information on Infinity, please refer to Infinity's website at
www.infi.com.
Contact:
Jayne
Kauffman, Infinity Pharmaceuticals, Inc.
P: 617-453-1198 or Jayne.Kauffman@infi.com
View original
content:http://www.prnewswire.com/news-releases/infinity-to-present-at-two-upcoming-conferences-in-september-300910337.html
SOURCE Infinity Pharmaceuticals, Inc.